Cardiometabolic risk factors and antithrombotic treatment in a Mexican population with atrial fibrillation and heart failure with reduced ejection fraction.

INTRODUCTION: Heart failure in patients with non-valvular atrial fibrillation (NVAF) is two to three times more common than in individuals without NVAF. OBJECTIVE: To identify cardiometabolic risk factors (CMRF) and antithrombotic treatment in patients with NVAF and heart failure with reduced ejection fraction (HFrEF), and to determine if there were differences according to gender. METHODS: CMRF, pro-thrombotic risk, bleeding risk, and antithrombotic therapy were globally analyzed and according to gender. RESULTS: Out of 1,423 patients with NVAF, 336 had HFrEF. On average, females were older than males. There was no difference between genders with regard to the type of NVAF or direct oral anticoagulants use. Hypertension was more common in women. History of transient ischemic attack was reported in 3.6% of the patients and cerebrovascular event in 10%, without differences in terms of gender. The percentage of men with elevated embolic risk was higher, but without antithrombotic treatment, in comparison with women. CONCLUSIONS: Significant differences were found according to gender in patients with NVAF and HFrEF, both in CMRF and some comorbidities, as well as in antithrombotic treatment according to embolic and bleeding risk.

INTRODUCCIÓN: La insuficiencia cardiaca en pacientes con fibrilación auricular no valvular (FANV) es de dos a tres veces más frecuente que en individuos sin FANV. OBJETIVO: Identificar los factores de riesgo cardiometabólico (FRCM) y el tratamiento antitrombótico de pacientes con FANV e insuficiencia cardiaca con fracción de expulsión reducida (IC-FEr), y determinar si existen diferencias conforme al sexo. MÉTODOS: En forma global y de acuerdo con el sexo se analizaron FRCM, riesgo protrombótico, riesgo de sangrado y terapia antitrombótica. RESULTADOS: De 1423 pacientes con FANV, 336 tuvieron IC-FEr. Las mujeres promediaron mayor edad que los hombres. No hubo diferencia entre los sexos respecto al tipo de FANV o uso de anticoagulantes orales directos. La hipertensión arterial sistémica fue más frecuente en mujeres. Un 3.6 % de los pacientes reportó antecedente de ataque isquémico transitorio y 10 % de evento vascular cerebral, sin diferencias en cuanto al sexo. El porcentaje de hombres con riesgo embólico elevado fue mayor, pero sin tratamiento antitrombótico, en comparación con las mujeres. CONCLUSIONES: Se encontraron diferencias significativas de acuerdo con el sexo en pacientes con FANV e IC-FEr, tanto en FRCM y algunas comorbilidades, como en el tratamiento antitrombótico de acuerdo con el riesgo embólico y de sangrado.

Factores de riesgo cardiometabólico y tratamiento antitrombótico en población mexicana con fibrilación auricular e insuficiencia cardiaca con fracción de expulsión reducida / Cardiometabolic risk factors and antithrombotic treatment in a Mexican population with atrial fibrillation and heart failure with reduced ejection fraction

Resumen Introducción: La insuficiencia cardiaca en pacientes con fibrilación auricular no valvular (FANV) es de dos a tres veces más frecuente que en individuos sin FANV. Objetivo: Identificar los factores de riesgo cardiometabólico (FRCM) y el tratamiento antitrombótico de pacientes con FANV e insuficiencia cardiaca con fracción de expulsión reducida (IC-FEr), y determinar si existen diferencias conforme al sexo. Métodos: En forma global y de acuerdo con el sexo se analizaron FRCM, riesgo protrombótico, riesgo de sangrado y terapia antitrombótica. Resultados: De 1423 pacientes con FANV, 336 tuvieron IC-FEr. Las mujeres promediaron mayor edad que los hombres. No hubo diferencia entre los sexos respecto al tipo de FANV o uso de anticoagulantes orales directos. La hipertensión arterial sistémica fue más frecuente en mujeres. Un 3.6 % de los pacientes reportó antecedente de ataque isquémico transitorio y 10 % de evento vascular cerebral, sin diferencias en cuanto al sexo. El porcentaje de hombres con riesgo embólico elevado fue mayor, pero sin tratamiento antitrombótico, en comparación con las mujeres. Conclusiones: Se encontraron diferencias significativas de acuerdo con el sexo en pacientes con FANV e IC-FEr, tanto en FRCM y algunas comorbilidades, como en el tratamiento antitrombótico de acuerdo con el riesgo embólico y de sangrado.

Abstract Introduction: Heart failure in patients with non-valvular atrial fibrillation (NVAF) is two to three times more common than in individuals without NVAF. Objective: To identify cardiometabolic risk factors (CMRF) and antithrombotic treatment in patients with NVAF and heart failure with reduced ejection fraction (HFrEF), and to determine if there were differences according to gender. Methods: CMRF, pro-thrombotic risk, bleeding risk, and antithrombotic therapy were globally analyzed and according to gender. Results: Out of 1,423 patients with NVAF, 336 had HFrEF. On average, females were older than males. There was no difference between genders with regard to the type of NVAF or direct oral anticoagulants use. Hypertension was more common in women. History of transient ischemic attack was reported in 3.6% of the patients and cerebrovascular event in 10%, without differences in terms of gender. The percentage of men with elevated embolic risk was higher, but without antithrombotic treatment, in comparison with women. Conclusions: Significant differences were found according to gender in patients with NVAF and HFrEF, both in CMRF and some comorbidities, as well as in antithrombotic treatment according to embolic and bleeding risk.

Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry.

Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients ≥18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects <65 years to 22.5% in those ≥75 years old (P <0.0001). Concomitantly, an increase in both APD and no antithrombotic treatment was observed with increasing age. DOAC were prescribed equally among all age groups (34.2% in <65, 36.0% in 65-74, and 33.9% in ≥75). According to the type of AF, VKA use was more common in patients with permanent AF (32.7%). A lower use of DOAC was observed in high thromboembolic risk subjects (33.6% in CHA2DS2-VASc ≥2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). Conclusions: VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT02334852. Highlights: CARMEN-AF is a nationwide multi-centric registry seeking to bridge the data gap on anticoagulation therapy for NVAF in Mexico.Elderly patients are more prone to receive suboptimal OAT for NVAF.DOAC were less frequently used in high thromboembolic risk patients (CHA2DS2-VASc ≥2).

Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registry.

BACKGROUND: Atrial Fibrillation (AF) is associated with an increased risk of stroke and systemic embolism. Several studies have suggested that female AF patients could have a greater risk for stroke. There is scarce information about clinical characteristics and use of antithrombotic therapies in Latin American patients with nonvalvular AF. OBJECTIVE: To describe the gender differences in clinical characteristics, thromboembolic risk, and antithrombotic therapy of patients with nonvalvular AF recruited in Mexico, an upper middle-income country, into the prospective national CARMEN-AF Registry. METHODS: A total of 1423 consecutive patients, with at least one thromboembolic risk factor were enrolled in CARMEN-AF Registry during a three-year period (2014-2017). They were categorized according to Gender. RESULTS: Overall, 48.6% were women, mean age 70 ±â€¯12 years. Diabetes, smoking, alcoholism, non-ischemic cardiomyopathy, coronary artery disease, and obstructive sleep apnea were higher in men. Most women were found with paroxysmal AF (40.6%), and most men with permanent AF (44.0%). No gender differences were found in the use of vitamin K antagonists (VKA) (30.5% in women vs. 28.0% in men). No gender differences were found in the use of direct oral anticoagulants (DOAC) (33.8% women vs 35.4% men). CONCLUSIONS: CARMEN-AF Registry demonstrates that in Mexico, regardless of gender, a large proportion of patients remain undertreated. No gender differences were found in the use of VKA or DOAC.

[Cardiac pacemaker dysfunction due to rotation of the battery (reel syndrome)]. / Disfunción del marcapasos por síndrome de reel.

Reel syndrome is characterized by the rotation of permanent pacemaker generator on its transverse axis and electrode catheters curl around it, so this causes displacement of the electrodes with the loss of atrial and ventricular pacing. It can cause severe symptoms due to dysfunction of the pacemaker. We present three patient cases who after the placement of pacemaker attended by dysfunction of the displacement of the electrodes their clinical pictures were compatible with Reel syndrome.

[Remote monitoring and follow up of implantable cardioverter defibrillators and cardiac resynchronization therapy devices]. / Monitoreo remoto y seguimiento del paciente con desfibrilador automático implantable y terapia de resincronización cardiaca.

INTRODUCTION: The implantable cardiac devices like regular pacemaker, cardiac resynchronization therapy (CRT) automatic implantable defibrillators (ICD) and CRT associate with ICD (CRTD) are now being used frequently. Patient visits to pacemaker and ICD clinics for review and monitoring, has increases significantly. We present the experience of monitoring via satellite of patients with implantable cardiac devices in Mexico. METHODS: Eighteen patients were selected from the arrhythmia Service Cardiac Electrophysiology and Stimulation of High Specialty Medical Unit (UMAE) of Specialties Hospital Dr. Antonio Fraga Mouret. National Medical Center (NMC) La Raza Mexican Social Security Institute (IMSS), who had a device (CRT, ICD y CRT-D) that is able to send information through the BIOTRONIK Home Monitoring system, from March 2006, to March 2009. RESULTS: We obtained 4,980 transmissions as reports and 149 alerts recorded events, of which 50 were in ventricular fibrillation, 14 in ventricular tachycardia, frequent ventricular extra systoles exceeded by the range allowed in one hour were 25, electrograms default 26; and atrial fibrillation at 11. CONCLUSIONS: The monitoring system via satellite is reliable and useful diagnostic tool, which permits early detection, opportune treatment and effective monitoring of implantable cardiac devices.

[New antiarrthythmics in atrial fibrillation]. / Nuevos antiarrítmicos en el tratamiento de fibrilación auricular.

Atrial fibrillation is the most common cardiac arrhythmia responsible for a significant morbidity and mortality. In recent years, progress has been made in determining the genetic abnormalities, the use of anticoagulants as a component of a primary treatment strategy in many patients who have a high risk of recurrence and for thromboembolism, and newer and safer antiarrthythmics are now available. The aim of this paper is to discuss about this topic and antiarrhythmic therapy.

Monitoreo remoto y seguimiento del paciente con desfibrilador automático implantable y terapia de resincronización cardiaca / Remote monitoring and follow up of implantable cardioverter defibrillators and cardiac resynchronization therapy devices

Introducción: Actualmente, el monitoreo de algunos dispositivos cardiacos implantables como los marcapasos y el desfibrilador automático, así como la terapia de resincronización cardiaca asociada con desfibrilador automático implantable, son los que se utilizan con mayor frecuencia y el seguimiento de los mismos se puede llevar a cabo por vía satelital; por ello su revisión y monitoreo ha incrementado las visitas presenciales en las clínicas de marcapasos y desfibriladores. A continuación se informa la experiencia de la monitorización vía satélite de dichos dispositivos en un centro hospitalario de tercer nivel. Métodos: Se seleccionaron 18 pacientes de la Clínica de Marcapasos del Servicio de Electro-fisiología y Estimulación Cardiaca de la Unidad Médica de Alta Especialidad del Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social a los cuales se les había implantado un desfibrilador o resincronizador con capacidad de vigilancia remota vía satélite (Home Monitoring BIOTRONIK, Alemania), de marzo del 2006 a marzo del 2009. Resultados: Como reportes, se obtuvieron 4980 transmisiones y 149 alertas por sucesos registrados, de los cuales 50 fueron de fibrilación ventricular, 14 de taquicardia ventricular, extrasístoles ventriculares frecuentes superadas por el rango permitido en una hora fueron 25, fibrilación auricular en 11. Conclusión: El sistema de vigilancia remota vía satélite es una herramienta de diagnóstico confiable, que permite una detección temprana de las principales arritmias que ocurren en los sujetos con dispositivos cardiacos implantables.

Introduction: The implantable cardiac devices like regular pacemaker, cardiac resynchronization therapy (CRT) automatic implantable defibrillators (ICD) and CRT associate with ICD (CRT-D) are now being used frequently. Patient visits to pacemaker and ICD clinics for review and monitoring, has increases significantly. We present the experience of monitoring via satellite of patients with implantable cardiac devices in Mexico. Methods: Eighteen patients were selected from the arrhythmia Service Cardiac Electrophysiology and Stimulation of High Specialty Medical Unit (UMAE) of Specialties Hospital Dr. Antonio Fraga Mouret. National Medical Center (NMC) La Raza Mexican Social Security Institute (IMSS), who had a device (CRT, ICD y CRT-D) that is able to send information through the BIOTRONIK Home Monitoring system, from March 2006, to March 2009. Results: We obtained 4,980 transmissions as reports and 149 alerts recorded events, of which 50 were in ventricular fibrillation, 14 in ventricular tachycardia, frequent ventricular extra systoles exceeded by the range allowed in one hour were 25, electrograms default 26; and atrial fibrillation at 11. Conclusions: The monitoring system via satellite is reliable and useful diagnostic tool, which permits early detection, opportune treatment and effective monitoring of implantable cardiac devices.

Beneficios clínicos de la resincronización cardiaca / Clinical benefit in cardiac resynchronization

Despite the improvement in pharmacologic treatment of heart failure, many patients continue to have severe persistent symptoms, and their prognosis remains poor. One of the most recent advances in heart failure management is the concept of cardiac resynchronization therapy (CRT). Large clinical trials have demonstrated morbidity and mortality benefits of CRT in patients with moderate to severe drug refractory heart failure (New York Heart Association [NYHA] functional class III or IV), and ejection fraction < or = 35% with QRS duration > or = 120 ms.

[Remote monitoring of automatic implantable cardiovascular devices (pacemakers, implantable cardioverter defibrillator and cardiac resynchronization)]. / Monitoreo a distancia de los dispositivos automáticos implantables cardiovasculares (marcapasos, desfibriladores automáticos implantables y resincronizadores cardiacos).

In the era of communication technology, new options are available to monitor patients with Automatic Implantable Cardiovascular Devices (AICD) implanted pacemaker (PM) and Automatic Implantable Defibrillators (AID) and Cardiac resynchronization system (CRS). Most companies offer devices with wireless capabilities to communicate automatically with transmitters, allowing remote monitoring device. These systems are being widely used in USA for remote monitoring and have been introduced more recently in Europe, where adoption is increasing. There have also been introduced some systems in Latin America; Mexico in particular has this type of monitoring. This article describes the systems currently existing, available data in the literature in relation to its monitoring and surveillance of the automatic implantable cardiovascular devices (DAIC) and finally, discuss some unresolved issues.

Monitoreo a distancia de los dispositivos automáticos implantables cardiovasculares (marcapasos, desfibriladores automáticos implantables y resincronizadores cardiacos) / Remote monitoring of automatic implantable cardiovascular devices (pacemakers, implantable cardioverter defibrillator and cardiac resynchronization)

In the era of communication technology, new options are available to monitor patients with Automatic Implantable Cardiovascular Devices (AICD) implanted pacemaker (PM) and Automatic Implantable Defibrillators (AID) and Cardiac resynchronization system (CRS). Most companies offer devices with wireless capabilities to communicate automatically with transmitters, allowing remote monitoring device. These systems are being widely used in USA for remote monitoring and have been introduced more recently in Europe, where adoption is increasing. There have also been introduced some systems in Latin America; Mexico in particular has this type of monitoring. This article describes the systems currently existing, available data in the literature in relation to its monitoring and surveillance of the automatic implantable cardiovascular devices (DAIC) and finally, discuss some unresolved issues.

[Clinical benefit in cardiac resynchronization]. / Beneficios clínicos de la resincronización cardiaca.

Despite the improvement in pharmacologic treatment of heart failure, many patients continue to have severe persistent symptoms, and their prognosis remains poor. One of the most recent advances in heart failure management is the concept of cardiac resynchronization therapy (CRT). Large clinical trials have demonstrated morbidity and mortality benefits of CRT in patients with moderate to severe drug refractory heart failure (New York Heart Association [NYHA] functional class III or IV), and ejection fraction < or = 35% with QRS duration > or = 120 ms.

[Infrequent electrocardiographic changes during exercise stress test in a patient with Brugada's syndrome]. / Alteraciones electrocardiográficas infrecuentes durante la prueba de tolerancia al ejercicio en un paciente con síndrome de Brugada.

38 year old patient with a syncope history and family background of sudden death had an electrocardiogram compatible with the "Brugada Syndrome". When an exercise stress testing with Bruce protocol was done, we found that during the effort phase and at maximum effort, contrary to a ST segment normalization, a discreet increase of the ST segment elevation of 2 mm in V1 and V2 occurred. During recovery phase a decrease in the ST segment elevation was observed, at a normal level as before the test.

[Trans-septal puncture for radiofrequency ablation of left accessory pathway]. / Punción transeptal para la ablación con radiofrecuencia de una vía accesoria izquierda.

We present the case of an 18-year-old male patient with diagnosis of Wolff Parkinson-White syndrome due to a left free wall accessory pathway. We performed an electrophysiology study and transseptal punction guided by transesophageal echocardiogram to via access to the left atrium. We performed successful radiofrequency ablation of the accessory pathway, observing disappearance of the delta wave on the first attempt. There were no complications. In follow-up a 10 months, the patient had no clinical nor electrocardiographic evidence of recurrence. Transseptal radiofrequency ablation is an alternative for treatment of some arrhythmias localized in the left side of the heart.

[Ventricular resynchronization in the treatment of heart failure]. / La resincronización ventricular en el tratamiento de la insuficiencia cardíaca.

Despite the major advances in medical drug therapy, heart failure remains a syndrome with high mortality and morbidity. Biventricular pacing is being tested in congestive heart failure patients with left bundle branch block of an advanced degree. The aim is to resynchronize the dyscoordinate left ventricle contraction. A number of studies are underway, but it is clear that while some patients respond remarkably, this method in highly variable. Accurate identification of patients likely to benefit will be crucial.

[Atrioventricular nodal reentrant tachycardia: Radiofrequency ablation]. / Taquicardia por reentrada nodal atrioventricular: ablación con radiofrecuencia.

Atrioventricular nodal reentrant tachycardia is the most frequent regular supraventricular tachycardia. It is generally a benign arrhythmia and usually it is no associated with heart disease. It is more often seen in middle-aged women but it is no infrequent in younger and older patients. The development of radiofrequency with catheter ablation has provided the possibility to definitely cure the arrhythmia and moreover permit a better comprehension of the underlying electrophysiologic and anatomic substrate.

[ Segmental ostial ablation to interrupt electrical conduction in a single pulmonary vein for the prevention of idiopathic paroxysmal atrial fibrillation]. / Ablación segmentaria del ostium de la vena pulmonar superior izquierda para eliminar actividad eléctrica anormal generadora de fibrilación atrial paroxística idiopática.

Several studies have shown the role of focal trigers in the pulmonary veins initiating episodes of atrial fibrillation. Radiofrequency catheter ablation of this foci is a curative therapy for paroxysmal atrial fibrillation. We report a case of idiopathic paroxysmal atrial fibrillation triggered by abnormal electrical activity in a single pulmonary vein. Mapping was performed during sinus rhythm with a 4F decapolar catheter (Spiral Supreme, Daig, St. Jude Medical) positioned near the ostium by a transseptal approach. Pulmonary vein potentials were only identified in the left superior pulmonary vein. Segmental ostial ablation (30 W) performed during left atrial pacing resulted in complete cesation of conduction in the pulmonary vein. There were no complications. The clinical response (suppression of the paroxysms of atrial fibrillation in a 9-month follow-up) observed in this patient imply that atrial fibrillation was triggered by this pulmonary vein. This case report illustrates several aspects of catheter-based ablation of pulmonary vein foci for the treatment of paroxysmal atrial fibrillation and demonstrates its efficacy.

Taquicardia por reentrada nodal atrioventricular: Ablación con radiofrecuencia / Atrioventricular nodal reentrant tachycardia: radiofrequency ablation

La taquicardia por reentrada nodal atrioventricular, es una de las causas más frecuentes de taquicardia supraventricular. Es generalmente una arritmia benigna y usualmente no está asociado a cardiopatía estructural, se presenta más frecuentemente en mujeres de media edad, pero no es infrecuente encontrarlo en personas jóvenes y en ancianos. El desarrollo de la ablación con radiofrecuencia a través de un catéter facilita la cura definitiva de la arritmia y permite una mejor compresión del sustrato anatómico electrofisiológico.

Atrioventricular nodal reentrant tachycardia is the most frequent regular supraventricular tachycardia. It is generally a benign arrhythmia and usually it is no associated with heart disease. It is more often seen in middle-aged women but it is no infrequent in younger and older patients. The development of radiofrequency with catheter ablation has provided the possibility to definitely cure the arrhythmia and moreover permit a better comprehension of the underlying electrophysiologic and anatomic substrate. (Arch Cardiol Mex 2003; 73:143-154).

[Follow-up of a group of patients with automatic implantable defibrillator]. / Seguimiento de un grupo de pacientes con desfibrilador automático implantable.

UNLABELLED: The automatic implantable defibrillator (AID) is the treatment of choice for primary and secondary prevention of sudden death. At the Instituto Nacional de Cardiología, since October 1996 until January 2002, 25 patients were implanted with 26 AID. There were 23 men (92%) and the mean age of the whole group, was 51.4 years. Twenty-three patients (92%) presented structural heart disease, the most common was ischemic heart disease in 13 patients (52%), with a mean ejection fraction of 37.8%. One patient without structural heart disease had Brugada Syndrome. The most frequent clinical arrhythmia was ventricular tachycardia in 14 patients (56%). The mean follow-up was of 29.3 months during which a total of 30 events of ventricular arrhythmia were treated through AID; six of them were inappropriate due to paroxismal atrial fibrillation; 10 AID patients (34%) have not applied for therapy. Three patients (12%) of the group died due to congestive heart failure refractory to pharmacologic treatment. CONCLUSION: The implant of the AID is a safe and effective measure for primary and secondary prevention of sudden death. World-wide experience evidences, that this kind of device has not modified the mortality rate due to heart failure in these patients, but it has diminished sudden arrhythmic death.